GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ironwood Pharmaceuticals Inc (NAS:IRWD) » Definitions » Interest Coverage

Ironwood Pharmaceuticals (Ironwood Pharmaceuticals) Interest Coverage : 4.48 (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Ironwood Pharmaceuticals Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Ironwood Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $43.2 Mil. Ironwood Pharmaceuticals's Interest Expense for the three months ended in Dec. 2023 was $-9.6 Mil. Ironwood Pharmaceuticals's interest coverage for the quarter that ended in Dec. 2023 was 4.48. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Ironwood Pharmaceuticals's Interest Coverage or its related term are showing as below:

IRWD' s Interest Coverage Range Over the Past 10 Years
Min: 3.2   Med: 7.45   Max: 32.95
Current: 7.82


IRWD's Interest Coverage is ranked worse than
58.95% of 687 companies
in the Drug Manufacturers industry
Industry Median: 12.08 vs IRWD: 7.82

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Ironwood Pharmaceuticals Interest Coverage Historical Data

The historical data trend for Ironwood Pharmaceuticals's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Ironwood Pharmaceuticals Interest Coverage Chart

Ironwood Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.20 5.37 7.45 32.95 7.78

Ironwood Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.95 53.42 15.15 4.74 4.48

Competitive Comparison of Ironwood Pharmaceuticals's Interest Coverage

For the Drug Manufacturers - Specialty & Generic subindustry, Ironwood Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ironwood Pharmaceuticals's Interest Coverage Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ironwood Pharmaceuticals's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Ironwood Pharmaceuticals's Interest Coverage falls into.



Ironwood Pharmaceuticals Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Ironwood Pharmaceuticals's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Ironwood Pharmaceuticals's Interest Expense was $-21.6 Mil. Its Operating Income was $168.3 Mil. And its Long-Term Debt & Capital Lease Obligation was $512.9 Mil.

Interest Coverage=-1* Operating Income (A: Dec. 2023 )/Interest Expense (A: Dec. 2023 )
=-1*168.336/-21.629
=7.78

Ironwood Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Ironwood Pharmaceuticals's Interest Expense was $-9.6 Mil. Its Operating Income was $43.2 Mil. And its Long-Term Debt & Capital Lease Obligation was $512.9 Mil.

Interest Coverage=-1* Operating Income (Q: Dec. 2023 )/Interest Expense (Q: Dec. 2023 )
=-1*43.21/-9.635
=4.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Ironwood Pharmaceuticals  (NAS:IRWD) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Ironwood Pharmaceuticals Interest Coverage Related Terms

Thank you for viewing the detailed overview of Ironwood Pharmaceuticals's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Ironwood Pharmaceuticals (Ironwood Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
100 Summer Street, Suite 2300, Boston, MA, USA, 02110
Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Executives
Marla L Kessler director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Andrew Davis officer: SVP, Chief Business Officer 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Sravan Kumar Emany officer: SVP, Chief Financial Officer 100 SUMMER ST, SUITE 2300, BOSTON MA 02109
Ronald Silver officer: Principal Accounting Officer 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Minardo John officer: Chief Legal Officer 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Thomas A Mccourt officer: Chief Commercial Officer C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Michael Shetzline officer: CMO,SVP,Head-Res&Drug 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Jason Rickard officer: SVP, Chief Operating Officer 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Mark G Currie officer: Chief Scientific Officer C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Julie Mchugh director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Sarissa Capital Management Lp 10 percent owner 660 STEAMBOAT ROAD, GREENWICH CT 06830
Alexander J Denner director C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Edward P Owens director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Gina Consylman officer: Chief Accounting Officer C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Kilroy Conor officer: SVP, GC & Secretary 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110

Ironwood Pharmaceuticals (Ironwood Pharmaceuticals) Headlines

From GuruFocus